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Abstract: The current paradigm of personalized medicine envisages the use of genomic data to
provide predictive information on the health course of an individual with the aim of prevention
and individualized care. However, substantial efforts are required to realize the concept: enhanced
genetic discoveries, translation into intervention strategies, and a systematic implementation in
healthcare. Here we review how further genetic discoveries are improving personalized prediction
and advance functional insights into the link between genetics and disease. In the second part we
give our perspective on the way these advances in genomic research will transform the future of
personalized prevention and medicine using Estonia as a primer.
Keywords: genetic discovery; genomic medicine; return of results; patient communication; biobank;
Estonia
1. Progress of Genomic Technologies Enabling Personalized Medicine
1.1. Overcoming the Limitations of Genetic Loci Discovery
1.1.1. Power Gains Through Sample Size Increase
Traditionally, one of the simplest ways to uncover substantially larger parts of the
so-called ‘missing heritability’—next to focusing on structural variants rather than single
nucleotide polymorphisms (SNPs)—is by simply increasing sample in genomic discovery
studies, which in turn increases statistical power [1]. From very early on, this has been
done through combining genome wide association study (GWAS) results of individual
studies in meta-analyses, facilitated by the formation of large GWAS consortia, which are
often phenotype-specific. The recognition by public bodies of earlier successes in genetic
discoveries through consortia and the importance of data-driven healthcare, led to the
creation of several biobanks, with the first initiatives having been established over 20 years
ago [2,3]. Currently, one of the most well-known public biobanks is the UK Biobank effort,
that aims to improve prevention, diagnosis, and treatment of illness, and the promotion of
health through society [4]. Up to now, roughly 500,000 samples have been collected with
both genetic data and a wide range of phenotypical measurements, which are available
for a small fee, to the wider scientific community in its entirety. Similar large public
efforts are Lifelines in the Netherlands [5] and the Estonian Biobank [6]. An interesting
source of biobank data comes from personal genomics companies such as 23andMe [7]
where participants can opt to make their genomes available (anonymized) to the scientific
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community, combined with data retrieved from self-reported health surveys. As of 2020
23andMe had reached a 12 million customers milestone, what makes it one of the largest
genetic research databases in the world.
1.1.2. Public Availability of GWAS (Results) Data
Significant increases in statistical power are furthermore facilitated by utilizing pub-
licly available data [8]. Large groundbreaking projects funded by the public such as the
Human Genome project typically made their findings publicly available. For institutional
projects (i.e., within non-governmental organizations/universities), however, retaining
the data privately in order to maximize the generation of scientific publications and au-
thorships has historically been the rule rather than the exception. There is a trend toward
more openly sharing data with researchers and the public [9–11]. The Wellcome Trust Case
Control Consortium (WTCCC) study on seven common diseases [12] was a frontrunner
in this regard, making the best use of often publicly funded research. This is exactly why
platforms such as the database of Genotypes and Phenotypes [13] or the European Genome
Phenome (EGA) [14] archives have been set up: facilitating easy data access and sharing.
The volume of data from GWAS from various consortia presents logistical challenges in
sharing data, but summary statistics from many of these studies are now available publicly,
for example, through the OpenGWAS project (https://gwas.mrcieu.ac.uk/ (accessed on
29 April 2021)). This allows easy combination of study statistics or replication, and can
be done even in the case of unknown proportions of sample overlaps by methods such
as METACARPA [15]. It further enables downstream analyses using GWAS summary
statistics only, such as large-scale Mendelian Randomization-like analyses using platforms
such as MR-Base [16], or LD score regressions using LD hub [17]. To ensure that the vast
amounts of generated data are not only publicly available, but also are truly accessible,
other models to improve the portability of data are being developed, such as methods
for decentralized storage of scientific data [18], and cloud-based models of multi-center
collaborations [19].
1.1.3. Increase in Resolution
Population Sequencing
Regardless of the sample size, genomic discoveries are dependent on variants that have
been identified through sequencing. As we continue to sequence many more individuals,
more variation is identified, and it has become clear that rarer variation may explain
parts of the missing heritability for complex traits [20]. Therefore, improving genomic
resolution is another feasible way to improve genomic discoveries, as has already been
demonstrated early on by comparing HapMap to 1000 Genomes imputation for various
traits and the observed improvement in terms of additional loci discovered and fine-
mapping [21]. Sequence efforts continue to grow and projects such as the Haplotype
Reference Consortium [22], which combine sequencing data from multiple cohorts, provide
greatly enriched imputation panels, the creation of which will substantially improve
genetic discoveries. A great number of population level whole genome sequence efforts
are underway, such as in the UK (n = 500,000 [23]), Australia (n = 200,000 [24]), France
(n = 235,000 [25]), and the USA (n = 1,000,000 [26]). Similar efforts to map and collect
human genetic variation are ongoing for non-European populations, such as the African
Genome Variation Project [27], H3Africa [28], Genome-Asia [29]. Multiple private sequence
efforts are also underway, one of the most ambitious being the effort of the AstraZeneca
to sequence 2 million human genomes [30], complemented by projects that will establish
deeper and more accurate reference maps of the human genome [31].
Addressing Neglected Parts of the Genome
Even though many genomes have been sequenced and analyzed, certain regions in the
genome are largely neglected in genome-wide analyses, such as the Y-chromosome or mito-
chondrial chromosomes. This is often due to complications in genotype calling, imputation,
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and selection of test statistics, as well as a lower proportion of genes, and a lower coverage
of current genotyping platforms compared with autosomal chromosomes [32–34]. There is
ample evidence for genetic regions in these chromosomes to be involved in a wide range of
traits and diseases, including auto-immune diseases [35–37]. Investing in the large-scale
analyses of these chromosomes, through efforts such as YGEN, the first international con-
sortium that will assess the influence of Y-chromosome variation on complex traits of public
health or evolutionary interest, are likely to provide a multitude of additional insights into
the contribution of variants on neglected chromosomes to complex traits [38]. Moreover,
mitochondrial work at scale is currently undertaken [39]. In a similar way, certain genetic
regions have been rarely analyzed due to the difficulty to type and impute these regions,
amongst the best-known examples immunologically are important complex regions such
as the HLA region and killer cell immunoglobulin-like receptors (KIRs). Recent methods
have however enabled the proper imputation of these regions [40,41], allowing the detailed
investigation of their role in human disease.
Fine-Mapping
With much higher resolution genomic data as compared to traditionally imputed
GWAS chip data, it becomes more likely that a causal variant will be present in the set of
analyzed variants. However, it remains difficult to identify these, because the vast majority
of associated variants fall outside the coding regions as recognized early on [42], whereas
the majority of annotation efforts have traditionally focused on coding variants [43]. Devel-
opments in fine-mapping approaches such as CADD [44] and Eigen [45] have integrated
extensive functional genomic annotations into a per-variant score of functionality, including
conservation scores, epigenomic annotations and protein-level consequence scores. This
importantly enables the prioritization of variants that are intergenic or in the non-coding
regions, where previously this was challenging. Other approaches such as CAVIARDB [46],
are able to highlight the most likely causal variants in a locus, just using summary statistics
and PICS [47], provides similar fine-mapping capabilities, but then also includes prior
knowledge such as transcriptional and epigenomic data, promising much improved fine-
mapping results. Further fine-mapping opportunities lie in genetic diversity between
populations, where differences in LD structure may help to further narrow down genetic
regions associated with a trait [48], thereby more accurately pinpointing the location of
actual causal variants. Studying different populations can improve the discovery of rare
risk variants in loci already highlighted by common variants found by GWAS, as has been
demonstrated in, for example, Greek isolates [49], or the Icelandic population [50].
1.1.4. Increase in Throughput and Moving towards ‘Big Data’
Genetic discovery can thus be greatly aided by increasing sample sizes in combination
with high-depth sequencing. This still comes at a substantial price, although the costs
of whole genome sequencing have been rapidly declining, nearing the USD 1000 dollar
genome barrier [51]. Newer developments offer further promise. One such technique
is nanopore or ‘strand sequencing’ which allow sequencing of longer reads and faster
phasing of genomes [52]. In concert with ever-increasing biobanking efforts are resulting
in large amounts of data for which need to be matched by raw computational power
and infrastructure. The quantity of data to organize and interpret has posed challenges,
requiring the development of appropriate tools to address these issues. On the genomics
analyses front, developments like Genotype Query Tools [53], provide novel data indexing
strategies and much improved data compression, resulting in substantial query analysis
performance improvements over current state-of-the-art tools of over 400-fold. In parallel,
analytical algorithms are continuously optimized, whereby borrowing techniques from
other fields of research such as signal processing [54] or artificial intelligence [55] offer
further improvements in deciphering the human genomic architecture.
Developments on the analytical infrastructure front continue to contribute to ever more
efficient genetic discovery. For example, sequencing pipelines, typically using algorithms
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running on high-end computer clusters on general CPUs, are being integrated in processors
themselves (i.e., ‘hard-coded’). The reconfigurable DRAGEN Bio-IT Processor, produced
by Illumina [56], has hard-coded highly optimized algorithms for the full next generation
sequencing (NGS) secondary analysis pipeline, which set world speed records for genomic
data analysis [57].
Solving data processing problems in big data genomics requires supercomputing
infrastructure and expertise, which are not always available in academic environments. In
industry, genomic big data management is tackled in various ways. Advanced genomics
companies make use of large-scale commercial cloud-computing infrastructures available
such as Amazon Web Services (AWS) or Google Genomics, to process and analyze sequence
data using clever open-source distributed tools such as Hadoop or Apache SPARK that
bring the algorithms to the data versus the much slower opposite. With the ever increasing
size of genomics data, big data approaches like the use of computing clouds and advanced
analytics platforms are already being adopted by the scientific community [58,59], simply
out of sheer necessity.
1.2. Increase in Understanding (from Genotype to Phenotype)
Discovery and interpretation of genetic trait variation requires insights from multiple
layers of biological intermediates through which genetic loci exert their effects on the phe-
notype in order to be able to obtain causal and mechanistic insights. This means integrating
genetic data with expression data (eQTL), regulatory elements and effectors, proteomes,
metabolomes, and intermediate phenotypes, all of which are interacting biological levels
that have their effects on the final outcome studied.
Large efforts have been undertaken to map epigenomic data, such as in the EN-
CODE [60] and Roadmap Epigenetics Project [61], Blueprint Epigenome [62], but also for
the proteome (HPP) [63] data exists on a comparable large scale. Efforts such as the Human
Cell Atlas [64] and HipSci [65], which enable the retrieval of these data simultaneously from
pluripotent stem cells allow insights in developmental and differentiation mechanisms on
a cellular level. However, another phenotypic level to be considered is the microbiome.
Apart from more intuitive associations of the microbiome with disease, such as inflamma-
tory bowel disease [66], there are also indications that it influences psychiatric [67] and
cardiovascular outcomes [68], whereas the composition of the microbiome itself is also
influenced by genetic variation of the host [69], which brings yet another dimension to
integrative genotype–phenotype analyses. Various efforts have been undertaken to obtain,
map and interpret the aforementioned data types.
Other efforts even aim to map entire organs, which have the potential to uncover
genetic effects on a precise organic scale. Examples include the UK Digital Heart Project [70],
having reconstituted entire human hearts from echocardiographs or ENIGMA [71] with
the world’s largest set of brain scans. Linking and integrating these biological data types
will on the one hand undoubtedly improve our understanding of higher-order networks
and mechanisms driving complex disease phenotypes across multiple tissues, but also
bring along a great challenge to build statistical models, although promising methods are
already available [72]. Many of the “omics” data can be readily integrated with genetic
data using imputation methods. For example, epigenomic markers [73] or expression
levels [74] that can be predicted based on cohort genotypes only. Imputation of epigenomes
is useful as trait-associated variants affect regulatory regions in a cell-type dependent
manner [75], and it is not always feasible to map every epigenetic mark in every tissue, cell
type and condition of interest. Imputation of epigenomes for specific cell-types enables
cell-type/tissue specific follow-up analyses to understand phenotype specific regulatory
consequences of variants identified. Similarly, eQTLs can be cell-type specific [76,77], and
appropriate cellular context enables a better understanding of variant consequences on
expression level in relevant tissue.
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1.3. Impact of Genetic Discoveries and Clinical Relevance
Translation of identified genetic variation or loci into pathogenic molecular mecha-
nisms appears more feasible than ever before and allow for the realization of personalized
medicine in practice. The need for such approaches is clear in clinical practice where the
marked differences in response to therapies between different individuals are a recognized
phenomenon, with drug response variability as a particularly well-studied case [78]. Medi-
cal conditions are personally unique when viewed at the molecular level; therefore, it only
makes sense if treatment options follow suit. Generic treatment options can potentially
have harmful consequences when “one size fits all” approaches are taken as evident from a
wealth of drug response studies. As of today, GWAS findings have already proven to be
clinically informative in a number of ways [79,80].
1.3.1. Risk Prediction and Causal Inference
A currently more directly applicable use of genomic discoveries is (genetic) risk
prediction of disease, where individual-level risk estimates through genomic risk scores
(GRS) may help in early intervention and improve diagnostic procedures. There have
been numerous studies developing risk prediction models using genetic markers and a
number of successful examples [81,82]. Notably, a recent study using nearly two million
genetic variants allowed stratification of individuals with different trajectories of CAD
solely based on genetic information, and performed better than conventional risk factors at
predicting incidence CAD [83]. With up to 2 million variants as a model for the genetic
architecture of CAD, it is virtually impossible to pinpoint specific causal mechanisms to
be used for intervention. Nevertheless, it is possible to perform causal inference using
genetic risk scores through Mendelian randomization (MR) analyses. In this specific use
of genetic risk scores, care must be taken however to design a risk score that instruments
a particular exposure that is hypothesized to impose a causal effect on the outcome. For
example, as previously suspected, it has been confirmed that LDL levels are causal to
CAD [84], stressing that LDL-cholesterol lowering interventions such as adjusted diets and
LDL lowering medication will have effects, as demonstrated also in a recent meta-analysis
of randomized, controlled trials (RCTs) [85]. Similar approaches will allow the discovery of
previously unknown causal risk factors that have the potential to aid disease management.
1.3.2. Disease Stratification and Tailored Clinical Surveillance/Management
Another application comes in the form of disease classification, where for example
Sirota and colleagues show that they were able to classify auto-immune diseases [86],
identifying variants that make an individual susceptible to one class of autoimmune disease
whilst simultaneously protecting from diseases in the other autoimmune class. This may
enable clinicians to more optimally tailor treatment, as certain drugs for example are known
to improve one type of autoimmune disorder, whilst having negative effects on another.
A good example for this is infliximab, which is an antibody that binds to TNF. Typically
prescribed and working well for rheumatoid arthritis and ankylosing spondylitis [87,88], it
however has no efficacy and sometimes even worsens the condition in individuals with
other autoimmune diseases such as multiple sclerosis [89].
1.3.3. Personalized Treatment
A major area where GWAS may play a role is in pharmacogenomics. As modern
medication only recently appeared as an environmental factor, it will not have caused any
negative evolutionary selection pressures on common variants associated with (severe)
adverse drug reactions (ADRs). Successful discoveries related to inflammatory disorders
include identification of loci for ADRs against Lumiracoxib [90], a drug that is prescribed
for the treatment of osteoarthritis and RA, causing liver injury, and loci associated with
ADRs against thiopurin [91,92], prescribed for autoimmune disorders such as Crohn’s
disease and rheumatoid arthritis, causing leukopenia and pancreatitis. In addition to the
discovery of genetic risk loci for ADRs, tailoring treatment doses of drugs depending on an
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individual’s genetic profile will also become valuable in clinical practice and has already
been demonstrated to be feasible for asthma [93].
GWAS can also aid in identifying drug targets [94,95]. By making clever use of known
well-established and up to date gene-drug target databases such as DrugBank [96], thera-
peutic target database (TTD) [97], and PharmGKB [98], one can overlap genes identified
in loci in a meta-analysis, or their interacting genes [99] and filter out those that appear
druggable for further study. As many of the compounds in these databases are already FDA
approved, this creates a wealth of opportunities for drug repurposing and repositioning,
bypassing the necessary lengthy and costly process of clinical safety trials.
2. Estonia as a Primer for Personalized Medicine
2.1. Favorable Circumstances
In all, genetic discoveries will continue to contribute in various ways to the realization
of personalized medicine [100], whereby personal biomarker-specific profiles affected by
genetic, clinical, and lifestyle factors are likely to play an important role [101] (Box 1).
The recognition of both the importance and the feasibility of personalized medicine for
common complex disorders for national public health has incentivized the Estonian gov-
ernment to start an ambitious biobanking initiative aiming to completely overhaul its
health-care system based on biologically informed personalized care, of which the resulting
precision medicine tools will be made available to everyone as part of the basic health
insurance coverage.
Box 1. The advent of personalized medicine.
It has long been recognized that standardized medical treatments, so called “one-size-fits-all”
approaches, may have serious limitations. The idea of personalized medicine is, therefore, not new,
but can be seen as an ongoing development. Prior to the biotech revolution of the last decades,
methods to determine detailed biological differences between humans and populations that could
be utilized for optimizing healthcare were limited. Decoding human DNA through the completion
of the Human Genome Project resulted in what can be regarded as the establishment of a blueprint
for the construction, development, and maintenance of the human organism. The HapMap project
that followed, made an inventory of DNA differences between individuals and provided the
groundwork for starting to understand inter-individual differences in genomic risk for disease.
This genomic data, in concert with other upcoming health data such as other omics measurements,
electronic health records (EHRs), and smart wearable devices can ultimately be devised to develop
personally optimized intervention strategies.
Genomic data in particular has been shown to be useful in guiding drug development. For example,
lead drug developer Astra Zeneca showed that genetically informed decisions not only led to an
increase in number of successful drug development projects, but also a reduced time to market [102].
Similarly, for personalized medicine, genetic profiling already helps optimizing drug dosage and
avoiding adverse effects, such as done for S-methyltransferase (TPMT) genotype testing prior to
administration of a class of drugs named thiopurines [103]. Additional genetic testing helps to
select medication for individuals with specific genetic mutations, an example being melanoma
patients with particular mutations in the BRAF gene developing resistance against the normally
used single agent BRAF inhibitors, who display a better response with combined use of MEK
inhibitors [104]. The advance of personalized medicine is demonstrated by the vast increase of
approved medication entering European and American markets, which define it generally as a
treatment that recommends or requires a biomarker pre-test to determine if a treatment is suitable
for a patient. In Germany, for example, according to this definition, there were no personalized
drugs on the market before 1996. The decade that followed, saw 10 oncological drugs becoming
available as personalized medicine, after which this number shot up to 63 in 2019, and diversified
over various disease classes [105].
Many nations have already launched initiatives to promote personalized medicine [106], but Estonia
in particular has shown to be on the forefront through its unique nation-wide integrated approach,
connecting a national biobank with electronic health records with the aim to incorporate it into
general healthcare.
This initiative is enabled by a number of aligning favorable circumstances. Firstly,
the progressive political climate in Estonia and attitude of its population support the
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adaptation of new technological developments, including personalized medicine. The
Estonian parliament was the first in the world to pass a special law to govern genome
research in the general population, the Human Genes Research Act [107]. This law is
favorable to the implementation of personalized medicine and provides the required legal
framework for it. The various acting governments throughout the lifespan of the initiative
have been overwhelmingly supportive of the initiative. Although, perhaps even more
important in this context is the positive attitude of the general public. Regularly conducted
surveys show that up to 75% of the respondents support the biobank, only 1% hold the
opposing view, and around 77% are interested in genetic testing [108] (Figure 1).
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Secondly, in the last decades Estonia has heavily invested in a first-class national IT
infrastructure and know-how, which has digitized many aspects of daily life. At the center
of this is the Estonian ID card—a computer-readable compulsory identification card imple-
mented in 2002 that gives access to a nationwide governmental technical infrastructure
called the X-road [109]. This is the central “digital highway” that gives access to all online
services in the country. The X-road is highly adaptable in the sense that new functionalities
can be added at any time. This includes the support for personalized medicine. The system
can be used to link major Estonian health registries and hospitals and facilitate sharing of
medical information for patients, such as health data history, hospital admissions, phar-
macy prescriptions, to compile a full medical picture to which treatments can be tailored in
a secure manner [110].
2.2. Biobank Cohort, Data Collected and Generated
The favorable circumstances culminated in the foundation of the National Biobank
(“Estonian Biobank”, EstBB) in 2001, which was transferred to the University of Tartu as
the Estonian Genome Center (EGCUT) in 2007. From 2002, it has built up its databases
and research portfolio ever since [6,111]. By 2011, the population-based biobank had
52,000 adult participants from the first wave of recruitment, and in 2018–2019 an additional
150,000 participants were recruited in the second wave. Altogether the biobank cohort
constitutes 20% of the country’s adult population. All projects described here are based on
the first 52,000 subjects in the EstBB, not on the whole cohort of 202,000 as it is today.
Blood samples were collected from all participants, which were subsequently used
for genotyping using the Illumina Infinium Global Screening Array, as well as for deep
phenotyping. Whole genome sequence data is currently available for 3000 individuals, as
well as whole exome sequencing for 2500 individuals and these numbers are continuously
increasing. Furthermore, EstBB has measured transcriptomics (Illumina RNAseq), DNA
methylation (Illumina 450 K methylation array), proteomics (Olink) as well as various
metabolomics profiles (clinical biochemistry, NMR, mass spectrometry) for a large number
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of participants to generate precise information based on molecular profiles. In 2018, the
EstBB launched a project for obtaining microbiome profiles from stool samples (over
2500 currently collected). Recently, a new contract was signed to expand the current
Nightingale NMR metabolomics dataset (https://nightingalehealth.com/ (accessed on
14 April 2021)) to all biobank participants in 2021–2022. In combination with regular
supplementation of electronic health status updates from registries, large scale longitudinal
studies are facilitated.
2.3. Translational Research in Genomics
The Estonian biobank legislation and consent allow return of scientific results to
biobank participants. The first projects involved a genotype first approach where biobank
participants with specific genetic findings were invited for further phenotyping and clinical
assessment while offering disclosure of genetic findings to the participant [112,113].
In 2017, a different approach was introduced offering a selection of results by the
biobank to participants who expressed interest in receiving them. As part of the process,
participants will update some measurements, update their lifestyle information and sign
the consent for return of results all through an online participant portal. Over a two-year
period, 2957 participants received the report accompanied with face-to-face counseling.
On top of disease risk prediction, EstBB is analyzing the potential impact of considering
pharmacogenomics in patient care [114]. This supports not only more tailored medication
dosages, but also allows avoiding ADRs and medication that might not even be effective
for a particular individual. Currently, the team at EstBB is able to profile 10 genes involved
in compound metabolism to give feedback about 31 different medications.
Furthermore, the biobank has put an extensive monitoring practice in place to ensure
and improve the quality of the entire process, with a focus on assessing the effect and
outcomes of receiving genomic risk information. Through the participant portal, each
participant is asked to fill out three questionnaires regarding the process: one before the
return of results visit, one immediately after it, and a third 6 months later. The results of this
pilot will inform future projects involving return of genomic risk information (manuscript in
preparation). For instance, when is face-to-face counseling necessary and when would other
modes, such as using the participant/patient portal for risk communication, be sufficient?
The most important result of these early translational studies, however, was the
subsequent decision of the Estonian government to invest substantially in order to increase
the biobank fourfold, to 200,000 subjects, and have all participants genotyped using arrays,
and sequence a subset of 3000 individuals to provide a population-based reference panel
for imputation of the array data.
2.4. National Personalized Medicine Pilot Projects
While previous projects were conducted in a research context, these national personal-
ized medicine pilots involve biobank participants as patients in clinical practice. To prepare
for a nation-wide personalized medicine system (Figure 2), Estonia has just finished the
two pilot projects involving participants of the EstBB, but conducted in the hospital set-
tings and by hospital-based physicians and primary care providers (GP’s) (manuscript
is in preparation). The main goals of these pilots were to test the feasibility of different
approaches in clinical practice and demonstrate the benefits of incorporating molecular
profiles in disease management in current clinical practice and in hospital IT structures.
Both of these national pilot projects involved 1000 biobank participants. The first
project focused on personalized risk prediction and management of breast cancer and
involves geneticists in combination with either primary care physicians or oncologists. The
second project involved family physicians and focuses on CAD.
J. Pers. Med. 2021, 11, 358 9 of 19
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Figure 2. Implementation of personalized medicine. Four core elements (circles) that represent strategic advantages enabling
the Estonian Personalized Medicine Initiative to be effectively realized.
The Estonian Biobank research projects as well as the national personalized medicine
clinical pilots are expected to lead to the gradual incorporation of personalized genome-
based medicine into general health care in Esto ia. The initial steps i this direction have
been taken by the Ministry of Social Affairs of t e Esto ian Government w n it announced
the launch of the Per on l Medicine Initiative in 2016 [115].
EstBB curr ntly already ctively participates in pr viding the genomic input both
through g nomic research and by providing he genotype information. Meanwhile other
par ners produced the necessary IT infrastructure change to allow genomic data to be
considered not separately but al ng with other health i formation, this i cludes pharma-
cogen mics integrated with the electronic prescription system, for instance.
As changes in medical care nd health informa ion of biobank articipants is regularly
updat d the risk predictions can be improved as new data comes in (Figure 3).
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3. Challenges and Pitfalls of Personalized Medicine Implementation in Estonia
and Beyond
3.1. Sci ntific Challenges
The current pilot proje ts focus on tackling common complex dis ases that have the
h ghest burden in th natio and are known to have a sub tantial enetic basis, being
type 2 diabetes, breast canc r, and CAD. One of the fir t major g als is to develop efficient
pr dictors for the risk of each disease by i tegrating genetic, health, and environmental
factors. The performance of the existing risk-prediction algorithms of the disease can be
enhanced by the addition of newly identified genetic components, making the resulting
risk estimates more personalized and accurate [116,117]. This in turn allows stratification
of individuals into categories of different risk levels, allowing to differentiate between
risk-reducing interventions targeted at those categories. Ultimately this will lead to an
increase of cost-efficiency of interventions and an improvement of their efficacy.
In this context, however, one of the challenges for researchers is to develop an efficient
genetic predictor capturing the polygenic nature of the heritable component of the disease.
The traditional approach for developing genetic risk prediction algorithms encompasses
the use of only a handful of genome-wide significant SNPs associated with a disease.
The biostatistics team at the EstBB that focuses on GRS methodology has demonstrated
that a polygenic risk score or ‘predictor’ that captures the effects of a large number of
genetic variants in an additive manner, has good predictive ability [117], an approach now
widely adopted [118]. Moreover, while conventionally the genetic variants are weighted
by their estimated regression coefficients from GWAS, the EstBB biostatistics team has
additionally demonstrated that further additional weighting can reduce biases in such
weights caused by what is known in statistics as the “winner’s curse” phenomenon [119]
and further improves the predictive accuracy. Such a doubly-weighted GRS has already
been developed for type 2 diabetes, where it has been shown that the actual risk level for
individuals with similar levels of conventional predictors (age, body mass index, physical
activity, and diet) may differ by more than three times depending on the level of the
GRS [117].
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3.2. Data Security and Privacy Challenges
A major concern when conducting genetic research using the EstBB data and samples
is honoring the need for privacy of the participants. Under no circumstances should the
participant confidentiality be compromised unless he/she reveals it personally.
Most countries have no specific law that regulates usage of genomic data, thereby
leaving a legal void that can lead to risky circumstances. For example, genetic information
can be valuable for insurance or employment purposes, as genetic tests can be used to
detect inherited conditions that might be costly to treat for the healthcare system, and
put a burden on employers. This generates concerns regarding for example employment
decisions, possibly the invocation of charging higher insurance premiums or even denial
of coverage [120], fears that are not unreasonable [121]. These fears can have various
consequences. Individuals denying genetic testing can miss out on health benefits these
tests can facilitate. Lack of trust can also result in skepticism toward research in genomics
and thereby result in decreased study participation, or even a reduction in funding.
Estonia, however, implemented a law in 2000 explicitly concerning the population
biobank and genomics data [107]. Specifically, it regulates how genome data are allowed to
be gathered and stored, to whom it belongs, and how it is allowed to be used in scientific
and commercial research. The key principle is that the owner of the genomic data is always
the individual. This is the basis of a robust system based on trust and transparency. All
participant data is pseudonymized, and only a handful of individuals have access to the
key that enables to link different types of data (phenotypes with genotype) [110]. Digital
security is further enhanced by data storage on systems that are completely separate from
the internet, making the system virtually unhackable from the outside.
3.3. Challenges in Communicating Research Results
Identifying high risk individuals early, focusing more on disease prevention, while
also increasing patients’ participation and responsibility in taking care of their own health
is expected to help decrease the burden of common complex disease in the long run. One
important issue is the automated decision support algorithms and AI tools analyzing the
vast and complex data and providing the report for the physician who has to commu-
nicate the content to the individual (who is or is not yet a patient). The complex nature
of risk determination and stratification through genomic and phenotype data, as well
as the probabilistic nature of the results are very likely to be beyond the grasp of the
general population.
Therefore, a challenge lies in the communication of these results, which are the
aggregate of multiple layers of health-related information (genetic, clinical, psychological,
etc.). To minimize the time spent on interpreting complex information, participants should
have this information presented in an understandable format and language, with guiding
visualizations and explanations (Figure 4 report example). Care must be taken that results
are returned together with proper medical support to provide interpretation and translation,
which includes genetic counseling, easy access to medical specialists and follow-up.
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Figure 4. Example page in the concept report for an Estonian biobank participant. In a personalized
report, th rticipant will receive inform tion how her/his risk of the diseas will increase as a
function of age, how much the genetic component has contributed to risk and to what extent it could
be altered by lifestyle modifications or medical intervention.
4. Future Outlook for Personalized Medicine in Estonia and Beyond
The EstBB project as well as the national personalized medicine clinical pilots are
expected to l ad to the gradual inc rporation of personal zed ge ome-based medicine
into g neral health care in Estonia (Box 2). The initial steps in this direction have been
taken by the Ministry of Social Affairs of the Estonian Government when it annou ced the
launch of the national Personal Medicine Initiative in 2016 together with a long list of other
stakeholders, including three other ministries, the main Estonian universities and hospitals,
as well as private IT solution providers [115]. This project is led by the Institute for Health
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and Development and will end in 2023. It is currently developing the first three genetically
informed decision tools to be used in clinical practice, which consist of polygenic risk scores
for breast/ovarian cancer, CAD, and pharmacogenomic traits.
Box 2. A future doctor visit.
When the Estonian National Personalized Medicine Initiative is in full effect, the healthcare system
in Estonia will be unlike any other system in the world. An individual born in 21st century
Estonia, will have their genome sequenced in high resolution early in adult life, for perhaps no
more than GBP 100. It then will be scanned for potential genomics risks for an array of common
complex diseases, as well as more high-risk Mendelian disorders and polymorphisms causing
adverse drug reactions. The results will be encrypted and stored in a secure database as part of the
national biobank. These data are accessible for the individual, who retains ownership and absolute
control over accessibility, but also for primary care and specialist physicians and pharmacists,
on the condition that the owner provided access permission. Doctor visits and regular health
checks populate the electronic health record database, and intelligent learning algorithms will
then utilize this new information to improve disease prediction models. During visits, the GP will
provide updated genomic risk profiles if needed, identify high risk lifestyle elements that need to be
adjusted, and then will devise lifestyle advice and monitoring priorities based on this information.
When medication is needed, potential suitable drugs for the treatment will first be cross-checked
against a pharmacogenetic profile for potential adverse reactions and potentially needed dose-
adjustments. The prescription is being prepared even before the participant leaves the consultation
room, and upon arrival at the pharmacy, a national ID card is scanned and medication picked-up
straightaway. Meanwhile, genomic and other health-related data is continuously growing and
being used (anonymized) by international scientific consortia to identify previously unknown
disease mutations and pharmacogenetically important genes. Once confirmed, these are fed back
into the database, and individuals with high-risk mutations are informed and invited for a consult
to provide suitable preventative care.
Some aspects of the national Personal Medicine Initiative already have tangible impact:
at the moment 99% of health data has been digitized, 99% of prescriptions are digital, and
100% of healthcare billing is digital [122]. Moreover, specifically in terms of genomics-
informed healthcare, selected findings in the framework of current pilot projects, such as
pharmacogenetic profiles, high-risk mutations, interpretation of polygenic risk scores, are
already being offered to involved participants. The national personalized medicine services
are continuously further improved by, for example, adding and developing follow-up smart
IT solutions such as clinical decision support software, but also increasing investments in
health management and surveillance and education are being made.
As certain genetic discoveries continue to be made, along with an ever-increasing
body of biological insights that are accepted and deposited in electronic health databases,
the best practices in personalized medicine will change with time. As such it is key
to periodically re-evaluate the medical risk information in light of newly accumulated
knowledge and adjust intervention and communication strategies accordingly. Continued
education and training of health professionals is also highly important so they are qualified
to effectively apply genomic tests and communicate the garnered results to their patients.
While family physicians are optimistic about envisioning genomics in their everyday
practice they too recognize that additional training is necessary [123]. To prepare the
physicians, genomic healthcare workshops are prepared, covering topics on genetic risk
scores, pharmacogenomics, and genetic counselling. Over the next two years 900 medical
professionals, mainly family physicians and nurses, will be able to participate. Additionally,
the National Institute for Health and Development is sending out a monthly newsletter to
keep health-care workers informed of developments in personalized medicine arena.
The potential of the Estonian personalized medicine initiative is boosted by the Es-
tonian biobank with over 200,000 participants, the latter representing nearly 20% of the
adult population. In the longer term the plan is to genotype most of the population, with
a customized genotyping chip that includes Estonia-specific genetic variation, allowing
the development of more precise genetic instruments for medical decision making. The
European Union recognizes the need for knowledge transfer and supports these initiatives
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through ample funding in Horizon Europe programme from 2021 to 2027. Estonia is
currently at the forefront of implementing eHealth services and genomic data in health
care in the EU, and is sharing its knowledge on national digital healthcare and biobanking
by participating actively in the EU Member States’ driven initiative “Towards access to at
least 1 Million Genomes in the EU by 2022” [124].
Though the future of personalized medicine is looking bright, the universal key to the
success of national personalized medicine projects will lie in education and demonstrating
the public benefits of genomic screening, and an unrelenting effort to execute these efforts
in a human rights framework that guarantee the ethical and secure use of data, and the
privacy and ultimate ownership of participants.
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